GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ETON · Dec 31, 2024

Eton Pharmaceuticals, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001437749-25-008136General Corporate

Debt relative to revenueRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.debt_to_revenue

76.42% · OPTIONAL · NOT_ENOUGH_HISTORY

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.07% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

2.48% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

23.29% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

39.05% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

60.01% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-6.66% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

8.34% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

8.11% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History11 statesHistory building

Dec 31, 20230/8 normalizedLevel 3 Mar 31, 20240/7 normalizedLevel 3 Jun 30, 20240/7 normalizedLevel 3 Sep 30, 20240/7 normalizedLevel 3 Dec 31, 20240/9 normalizedLevel 3 Mar 31, 20250/9 normalizedLevel 3 Jun 30, 20250/8 normalizedLevel 3 Sep 30, 20250/8 normalizedLevel 3 Dec 31, 20257/9 normalizedLevel 3 Mar 31, 20267/8 normalizedLevel 3 Jun 30, 20267/8 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Increased

Previous: 0.00%
Current: 0.07%
Delta: 0.07%

Cash Generation Decreased

Previous: 28.59%
Current: 2.48%
Delta: -26.11%

Inventory Pressure Increased

Previous: 18.77%
Current: 39.05%
Delta: 20.27%

Margin Decreased

Previous: 61.04%
Current: 60.01%
Delta: -1.03%

Profitability Decreased

Previous: 4.93%
Current: -6.66%
Delta: -11.59%

R And D Intensity Increased

Previous: 4.89%
Current: 8.34%
Delta: 3.45%

Sbc Intensity Decreased

Previous: 23.08%
Current: 8.11%
Delta: -14.97%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · ETON Fundamental State →Has State · Eton Pharmaceuticals, Inc. →Transitioned To · ETON R_AND_D_INTENSITY_INCREASED →Transitioned To · ETON SBC_INTENSITY_DECREASED →Transitioned To · ETON Fundamental State →Transitioned To · ETON CAPEX_INTENSITY_INCREASED →Transitioned To · ETON CASH_GENERATION_DECREASED →Transitioned To · ETON INVENTORY_PRESSURE_INCREASED →Transitioned To · ETON MARGIN_DECREASED →Transitioned To · ETON PROFITABILITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.